1. Integrating tobacco treatment into lung cancer screening practices: Study protocol for the Screen ASSIST randomized clinical trial
- Author
-
Caylin Marotta, Joanne Sheppard, Saif Hawari, Nancy A. Rigotti, Inga T. Lennes, Grace M Styklunas, Sydney Howard, Amy J. Wint, Douglas E. Levy, Elise Noonan, Sydney Crute, Elyse R. Park, Kimberly A. Harris, Francine L. Jacobson, Efren J. Flores, Irina Gonzalez, Yuchiao Chang, Jennifer S. Haas, and Jordan M. Neil
- Subjects
Teachable moment ,medicine.medical_specialty ,Lung Neoplasms ,Referral ,media_common.quotation_subject ,Context (language use) ,Telehealth ,Article ,law.invention ,Randomized controlled trial ,law ,Tobacco ,Medicine ,Humans ,Pharmacology (medical) ,Early Detection of Cancer ,media_common ,Randomized Controlled Trials as Topic ,integumentary system ,business.industry ,General Medicine ,Tobacco Products ,Abstinence ,Nicotine replacement therapy ,Telemedicine ,Tobacco Use Cessation Devices ,Family medicine ,Quality of Life ,Smoking Cessation ,business ,Lung cancer screening - Abstract
Background Integrating tobacco treatment services into lung cancer screening (LCS) has the potential to leverage a 'teachable moment' to promote cessation among long-term smokers and reduce disparities in tobacco treatment access. This protocol paper describes the Screen ASSIST (Aiding Screening Support in Stopping Tobacco) trial, which will identify how to best deliver evidence-driven tobacco treatment in the context of LCS. Methods Screen ASSIST is a randomized clinical trial with a 3-factor, fully crossed factorial design that enrolls current smokers (any cigarette use in the past 30 days) scheduled to attend LCS at multiple sites in the Mass General Brigham healthcare system. To maximize reach, recruitment is conducted at 3 time points: 1) at the time of LCS scheduling, 2) at the LCS visit, and 3) after the participant has received their LCS results. Participants are stratified by LCS study site and recruitment point and randomly assigned into 8 groups that test intervention components varying on telehealth counseling duration (4 weeks vs. 8 weeks), nicotine replacement therapy duration (2 weeks vs. 8 weeks), and systematic screening and referral for social determinants of health via a service named 'AuntBertha' (referral vs. no referral). The primary study outcome is self-reported past 7-day tobacco abstinence at 6-month follow-up. This trial will also assess systems integration and evaluate implementation of the intervention. Discussion Screen ASSIST will identify the most effective combination of tobacco cessation treatments within the LCS context, in order to improve the cost-effectiveness of LCS and quality of life among long-term heavy smokers.
- Published
- 2021